Download PDF
Dtsch Med Wochenschr 2012; 137(15): 799-801
DOI: 10.1055/s-0031-1299006
Kommentar | Commentary
Kardiologie, Gastroenterologie
© Georg Thieme Verlag KG Stuttgart · New York

Thrombozytenaggregationshemmer und Protonenpumpeninhibitoren: Unsicherheiten beseitigt?

Platelet inhibitors and proton pump inhibitors: no more uncertainties?
C. Jacobshagen
1   Abteilung Kardiologie und Pneumologie, Herzzentrum, Georg-August-Universität Göttingen
,
G. Hasenfuß
1   Abteilung Kardiologie und Pneumologie, Herzzentrum, Georg-August-Universität Göttingen
› Author Affiliations
Further Information

Publication History

07.02.2012

17.02.2012

Publication Date:
10 April 2012 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Thrombozxytenaggregationshemmer - Protonenpumpenhemmer - gastrointestinale Blutung - akutes Koronarsyndrom

Keywords

platelet inhibitors - proton pump inhibitors - gastrointestinal bleeding - acute coronary syndrome
 

  • Literatur

  • 1 Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
    CrossrefPubMedGoogle Scholar
  • 2 Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-1917
    CrossrefPubMedGoogle Scholar
  • 3 Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317
    CrossrefPubMedGoogle Scholar
  • 4 Fischbach W, Darius H, Gross M et al. Concomitant use of thrombocyte aggregation inhibitors and proton pump inhibitors (PPIs). Z Gastroenterol 2011; 49: 395-402
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009; 47: 1230-1263
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Frere C, Cuisset T, Morange PE et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008; 101: 1088-1093
    CrossrefPubMedGoogle Scholar
  • 7 Gaglia Jr MA, Torguson R, Hanna N et al. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol 2010; 105: 833-838
    CrossrefPubMedGoogle Scholar
  • 8 Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260
    CrossrefPubMedGoogle Scholar
  • 9 Gilard M, Arnaud B, Le GG et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 2508-2509
    CrossrefPubMedGoogle Scholar
  • 10 Goodman SG, Clare R, Pieper KS et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: Insights from PLATO. Circulation 2012; Jan 18. [Epub ahead of print]
    PubMedGoogle Scholar
  • 11 Grines CL, Bonow RO, Casey DE et al. Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. Circulation 2007; 115: 813-818
    CrossrefPubMedGoogle Scholar
  • 12 Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054
    CrossrefPubMedGoogle Scholar
  • 13 Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944
    CrossrefPubMedGoogle Scholar
  • 14 Hulot JS, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247
    CrossrefPubMedGoogle Scholar
  • 15 Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718
    CrossrefPubMedGoogle Scholar
  • 16 Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction?. Am J Gastroenterol 2010; 105: 34-41
    CrossrefPubMedGoogle Scholar
  • 17 Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362
    CrossrefPubMedGoogle Scholar
  • 18 Ng FH, Lam KF, Wong SY et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 2008; 77: 173-177
    CrossrefPubMedGoogle Scholar
  • 19 O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997
    CrossrefPubMedGoogle Scholar
  • 20 Rassen JA, Choudhry NK, Avorn J et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-2329
    CrossrefPubMedGoogle Scholar
  • 21 Ray WA, Murray KT, Griffin MR et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152: 337-345
    CrossrefPubMedGoogle Scholar
  • 22 Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007; 2: 93-109
    CrossrefPubMedGoogle Scholar
  • 23 Serebruany VL, Malinin AI, Ferguson JJ et al. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol 2008; 22: 315-321
    CrossrefPubMedGoogle Scholar
  • 24 Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518
    CrossrefPubMedGoogle Scholar
  • 25 Silber S, Borggrefe M, Böhm M et al. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES). Kardiologe 2007; 2: 84-111
    PubMedGoogle Scholar
  • 26 Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375
    CrossrefPubMedGoogle Scholar
  • 27 Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010; 170: 704-710
    CrossrefPubMedGoogle Scholar
  • 28 Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934
    CrossrefPubMedGoogle Scholar
  • 29 Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
    CrossrefPubMedGoogle Scholar
  • 30 Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555
    CrossrefPubMedGoogle Scholar
  • 31 Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
    CrossrefPubMedGoogle Scholar
  • 32 Writing Committee et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation 2010; 122: 2619-2633
    CrossrefPubMedGoogle Scholar
  • 33 Writing Committee et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation 2008; 118: 1894-1909
    CrossrefPubMedGoogle Scholar
  • 34 Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
    CrossrefPubMedGoogle Scholar